• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Biol Chem . Reversible and irreversible inhibitors of coronavirus Nsp15 endoribonuclease

tetano

Editor, Senior Moderator
J Biol Chem


. 2023 Oct 11:105341.
doi: 10.1016/j.jbc.2023.105341. Online ahead of print. Reversible and irreversible inhibitors of coronavirus Nsp15 endoribonuclease

Jerry Chen[SUP] 1 [/SUP], Rabih Abou Farraj[SUP] 2 [/SUP], Daniel Limonta Velazquez[SUP] 3 [/SUP], Seyed Amir Tabatabaei Dakhili[SUP] 4 [/SUP], Evan M Kerek[SUP] 1 [/SUP], Ashim Bhattacharya[SUP] 5 [/SUP], Filip M Reformat[SUP] 1 [/SUP], Ola M Mabrouk[SUP] 6 [/SUP], Benjamin Brigant[SUP] 7 [/SUP], Tom A Pfeifer[SUP] 8 [/SUP], Mark T McDermott[SUP] 6 [/SUP], John R Ussher[SUP] 4 [/SUP], Tom C Hobman[SUP] 9 [/SUP], J N Mark Glover[SUP] 2 [/SUP], Basil P Hubbard[SUP] 10 [/SUP]



Affiliations
Free article Abstract

The emergence of SARS-CoV-2, the causative agent of COVID-19, has resulted in the largest pandemic in recent history. Current therapeutic strategies to mitigate this disease have focused on the development of vaccines and on drugs that inhibit the viral 3CL protease or RNA-dependent RNA polymerase enzymes. A less-explored and potentially complementary drug target is Nsp15, a uracil-specific RNA endonuclease that shields coronaviruses and other nidoviruses from mammalian innate immune defenses. Here, we perform a high-throughput screen of over 100,000 small molecules to identify Nsp15 inhibitors. We characterize the potency, mechanism, selectivity, and predicted binding mode of five lead compounds. We show that one of these, IPA-3, is an irreversible inhibitor that might act via covalent modification of Cys residues within Nsp15. Moreover, we demonstrate that three of these inhibitors (Hexachlorophene, IPA-3, and CID5675221) block SARS-CoV-2 replication in cells at sub-toxic doses. This study provides a pipeline for the identification of Nsp15 inhibitors, and pinpoints lead compounds for further development against COVID-19 and related coronavirus infections.

Keywords: COVID-19; COVID-19 therapeutics; IPA-3; Nsp15; RNA endonucleases; SARS-CoV-2; coronaviruses; hexachlorophene; high-throughput chemical screen; immune evasion; nidoviruses; small-molecule inhibitors.

 
Back
Top Bottom